ADMA Biologics Inc(ADMA) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Current Price

$1.74

RSI

40.362

Beta:

1.315499

November 05, 2020
100.2M
-26.7M

42.283 %
46.706 %
-47.900 %
-11.850 %

$29,349,083
$16,985,290
$22,760,560
$10,661,037
$7,177,633
$5,915,545
72.791 %
-34.002 %
113.493 %
48.531 %
21.335 %

$-48,279,317
$-65,743,445
$-43,758,975
$-19,515,151
$-17,969,930
$-17,364,887
36.173 %
-33.440 %
-55.403 %
-7.918 %
-3.367 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.